751 SARS-CoV-2 infected patients with intestinal parasitic infection were enrolled. Patients co-infected with parasites had lower odds of developing severe COVID-19.
Only 27/255 (10.6%) severe COVID-19 patients were co-infected with intestinal parasites, while 257/496 (51.8%) non-severe COVID-19 patients were parasite positive (p<0.0001). Patients co-infected with parasites had lower odds of developing severe COVID-19, with an adjusted odds ratio (aOR) of 0.23 (95% CI 0.17–0.30; p<0.0001) for all parasites, aOR 0.37 ([95% CI 0.26–0.51]; p<0.0001) for protozoa, and aOR 0.26 ([95% CI 0.19–0.35]; p<0.0001) for helminths.
Interpretation: Parasite co-infection is associated with a reduced risk of severe COVID-19 in African patients. Parasite-driven immunomodulatory responses may mute hyper-inflammation associated with severe COVID-19.
Just please, don’t try this at home folks!
Ivermectin definitely should not be taken when infected with SARS-CoV-2 😉
Co-infection with parasites considerably lowers risk for severe COVID.https://t.co/IqrhMet0dZ
— Gönndalf (@drallcome) January 22, 2022
Image of Trichuris trichiura by By Daniel J. Drew – https://www.gbif.org/occurrence/1571554104, CC0, https://commons.wikimedia.org/w/index.php?curid=86159945
A 55-year-old male arrived at the hospital with HIV, Covid-19 and tuberculosis. On June 6, 2021, the patient recovered and was discharged after 10 days in hospital
This case report suggests, after 10 days of admission with triple infections, there is a good clinical prognosis and survival from COVID-19. On admission, further diagnosis and investigations of TB coinfection should be performed for all patients admitted with COVID-19 due to their similar and non-specific clinical manifestations.